NEW YORK, Feb. 13 /PRNewswire-FirstCall/ -- China Aoxing Pharmaceutical Company, Inc. today announced that the Company will present at the Roth Capital Partners 19th Annual OC Investor Conference on February 21, 2007 at the Ritz Carlton in Laguna Niguel, CA. Management is currently scheduled to present at 12:30 pm PT. Listeners may access a live webcast of the presentation by visiting the Roth Capital webcast link at http://www.wsw.com/webcast/roth9/caxg.ob/.
Investors who would like more information about attending the Roth Capital OC Investor Conference should contact their Roth Capital Partners sales representative.
About China Aoxing Pharmaceutical Company
Hebei Aoxing Pharmaceutical Group is a corporation organized under the laws of the People's Republic of China that has developed a patented manufacturing process for a variety of generic analgesic drugs, including Oxycodone, Pholcodine, Naloxone, and Tilidine. Hebei Aoxing is one of only a handful of companies in China to be granted the license to manufacture these drugs and is working closely with the Chinese government to assure their availability throughout China. China Aoxing Pharmaceutical Company acquired Hebei Aoxing in a reverse merger transaction in April of 2006.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. You are urged to read the Company's filings with the Securities and Exchange Commission, including, but not limited to, the risk factors contained therein. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
China Aoxing Pharmaceutical Company
CONTACT: Dr. Hui Shao, Senior Vice President of China AoxingPharmaceutical, +1-201-420-1075; Ashley M. Ammon & Bill Zima of IntegratedCorporate Relations, Inc., +1-203-682-8200
